It’s not that AE37 doesn’t work on higher her2

It’s not that AE37 doesn’t work on higher her2 expressing breast cancer patients, it’s that those control patients received Herceptin which is very effective. So DFS didn’t get the p value to show improvement. That was more of a trial design error much discussed in the past. Triple negative patients don’t benefit from Herceptin so we see a clearer comparison to access the vaccine.